Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QGEN Stock Forecast 2025-2026
$48.13
Current Price
$10.42B
Market Cap
Buy 9
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to QGEN Price Targets
+14.3%
To High Target of $55.00
+3.9%
To Median Target of $50.00
-6.5%
To Low Target of $45.00
QGEN Price Momentum
+1.3%
1 Week Change
+2.2%
1 Month Change
+14.1%
1 Year Change
+8.1%
Year-to-Date Change
-1.6%
From 52W High of $48.90
+27.9%
From 52W Low of $37.63
📊 TOP ANALYST CALLS
Did QGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if QIAGEN is one of their latest high-conviction picks.
Latest QGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, QGEN has a bullish consensus with a median price target of $50.00 (ranging from $45.00 to $55.00). The overall analyst rating is Buy (7.8/10). Currently trading at $48.13, the median forecast implies a 3.9% upside. This outlook is supported by 9 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Luke Sergott at Barclays, projecting a 14.3% upside. Conversely, the most conservative target is provided by Daniel Arias at Stifel, suggesting a 6.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QGEN Analyst Ratings
9
Buy
7
Hold
0
Sell
QGEN Price Target Range
Low
$45.00
Average
$50.00
High
$55.00
Current: $48.13
Latest QGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 26, 2025 | B of A Securities | Derik De Bruin | Buy | Maintains | $53.00 |
| Jun 24, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $55.00 |
| Apr 21, 2025 | Baird | Catherine Schulte | Neutral | Maintains | $43.00 |
| Apr 4, 2025 | Redburn Atlantic | Ed Ridley-Day | Neutral | Downgrade | $0.00 |
| Feb 19, 2025 | Baird | Catherine Schulte | Neutral | Downgrade | $42.00 |
| Feb 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $48.00 |
| Jan 6, 2025 | Morgan Stanley | Steve Beuchaw | Equal-Weight | Downgrade | $48.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Buy | Upgrade | $54.00 |
| Oct 17, 2024 | HSBC | Shubhangi Gupta | Hold | Downgrade | $0.00 |
| Aug 2, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $52.00 |
| Jun 27, 2024 | Wolfe Research | Doug Schenkel | Outperform | Upgrade | $50.00 |
| Jun 18, 2024 | JP Morgan | Casey Woodring | Overweight | Maintains | $54.00 |
| May 1, 2024 | Stifel | Daniel Arias | Hold | Maintains | $45.00 |
| Feb 16, 2024 | Morgan Stanley | Steve Beuchaw | Overweight | Upgrade | $51.00 |
| Feb 8, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $60.00 |
| Feb 8, 2024 | JP Morgan | Tycho Peterson | Overweight | Maintains | $52.00 |
| Dec 20, 2023 | JP Morgan | Tycho Peterson | Overweight | Maintains | $50.00 |
| Dec 19, 2023 | Wells Fargo | Timothy Daley | Equal-Weight | Initiates | $44.00 |
| Dec 13, 2023 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $0.00 |
| Dec 7, 2023 | Goldman Sachs | Matthew Sykes | Buy | Upgrade | $0.00 |
Qiagen N.V. (QGEN) Competitors
The following stocks are similar to QIAGEN based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Qiagen N.V. (QGEN) Financial Data
Qiagen N.V. has a market capitalization of $10.42B with a P/E ratio of 111.9x. The company generates $2.00B in trailing twelve-month revenue with a 4.7% profit margin.
Revenue growth is +5.4% quarter-over-quarter, while maintaining an operating margin of +25.9% and return on equity of +2.7%.
Valuation Metrics
Market Cap
$10.42B
Enterprise Value
$10.85B
P/E Ratio
111.9x
PEG Ratio
21.0x
Price/Sales
5.2x
Growth & Margins
Revenue Growth (YoY)
+5.4%
Gross Margin
+63.8%
Operating Margin
+25.9%
Net Margin
+4.7%
EPS Growth
+12.5%
Financial Health
Cash/Price Ratio
+9.3%
Current Ratio
3.4x
Debt/Equity
41.4x
ROE
+2.7%
ROA
+5.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Qiagen N.V. (QGEN) Business Model
About Qiagen N.V.
What They Do
Biotechnology company providing molecular testing solutions.
Business Model
Qiagen N.V. generates revenue by offering a wide range of sample and assay technologies that are crucial for molecular testing. The company serves multiple sectors, including academic research, pharmaceuticals, clinical diagnostics, and applied testing, by providing innovative products that facilitate the isolation, purification, and analysis of DNA, RNA, and proteins.
Additional Information
Established in 1984, Qiagen is a market leader in the biotechnology space, with a strong focus on advancing genomic science and diagnostics. The company collaborates with research institutions and healthcare providers to enhance disease detection and patient care, emphasizing its commitment to scientific progress and quality healthcare outcomes.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
5,700
CEO
Mr. Thierry Bernard
Country
Netherlands
IPO Year
1996
Website
www.qiagen.comQiagen N.V. (QGEN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
QGEN or EXAS: Which Is the Better Value Stock Right Now?
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Jul 10, 2025
By Zacks Equity Research
Tale of the Tape
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jul 10, 2025
By Zacks Equity Research
Tale of the Tape
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jul 07, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
QIAGEN N.V. will release its Q2 2025 financial results and hold a webcast to discuss the results, as announced from Venlo, Netherlands.
Why It Matters
QIAGEN's Q2 2025 results and webcast will provide insights into its financial performance and strategy, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Investors in the Medical - Biomedical and Genetics sector might consider Qiagen (QGEN) and Exact Sciences (EXAS) for potential value opportunities.
Why It Matters
The comparison of Qiagen and Exact Sciences highlights potential investment opportunities in the biomedical sector, influencing stock selection and portfolio strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
QIAGEN N.V. has elected Stephen H. Rusckowski as Chairman, effective June 26, 2025, succeeding Lawrence A. Rosen, who completed 12 years on the Supervisory Board.
Why It Matters
Leadership changes can impact a company's direction and strategy. Stephen H. Rusckowski's election may signal shifts in governance and operational focus, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Here's Why Qiagen (QGEN) is a Strong Value Stock
19 days ago
Quick Summary
Zacks Premium research service offers Zacks Style Scores, aiding value, growth, and momentum investors in identifying strong stocks.
Why It Matters
The Zacks Style Scores can enhance stock-picking strategies, potentially leading to better investment decisions and improved portfolio performance across various investment styles.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
QIAGEN N.V. (QGEN) has reached a key level of support, indicating a potentially favorable technical position for investors.
Why It Matters
QIAGEN N.V. hitting a key support level may indicate a potential price rebound, attracting buyers and influencing market sentiment positively.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical - Biomedical and Genetics sector are comparing Qiagen (QGEN) and Exact Sciences (EXAS) for potential value opportunities.
Why It Matters
The comparison of Qiagen and Exact Sciences highlights potential investment opportunities, indicating which stock may provide better value and returns in the biomedical sector.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About QGEN Stock
What is Qiagen N.V.'s (QGEN) stock forecast for 2026?
Based on our analysis of 19 Wall Street analysts, Qiagen N.V. (QGEN) has a median price target of $50.00. The highest price target is $55.00 and the lowest is $45.00.
Is QGEN stock a good investment in 2026?
According to current analyst ratings, QGEN has 9 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $48.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QGEN stock?
Wall Street analysts predict QGEN stock could reach $50.00 in the next 12 months. This represents a 3.9% increase from the current price of $48.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Qiagen N.V.'s business model?
Qiagen N.V. generates revenue by offering a wide range of sample and assay technologies that are crucial for molecular testing. The company serves multiple sectors, including academic research, pharmaceuticals, clinical diagnostics, and applied testing, by providing innovative products that facilitate the isolation, purification, and analysis of DNA, RNA, and proteins.
What is the highest forecasted price for QGEN Qiagen N.V.?
The highest price target for QGEN is $55.00 from Luke Sergott at Barclays, which represents a 14.3% increase from the current price of $48.13.
What is the lowest forecasted price for QGEN Qiagen N.V.?
The lowest price target for QGEN is $45.00 from Daniel Arias at Stifel, which represents a -6.5% decrease from the current price of $48.13.
What is the overall QGEN consensus from analysts for Qiagen N.V.?
The overall analyst consensus for QGEN is bullish. Out of 19 Wall Street analysts, 9 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $50.00.
How accurate are QGEN stock price projections?
Stock price projections, including those for Qiagen N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 5:46 PM UTC